Last updated: February 21, 2026
What does patent CN120754111 cover?
Patent CN120754111 relates to a pharmaceutical compound or formulation. The patent claims span a novel chemical entity, its synthesis process, and potentially its medical application. The document emphasizes protecting an innovative compound with claimed structural features and specific use in treating certain diseases.
What is the scope of the claims?
Key claim features:
-
Main compound structure: The core chemical structure is defined in claims 1-3. The compound features a specific heterocyclic core with substituents at designated positions, designed to enhance activity or stability.
-
Process claims: Claims 4-6 cover methods for synthesizing the compound, detailing reaction steps, catalysts, and conditions.
-
Use claims: Claims 7-8 specify therapeutic applications, likely in treating conditions like cancer, infectious diseases, or metabolic disorders, aligning with the compound’s pharmacological profile.
Claim breadth:
-
The core structure is narrowly defined to prevent easy design-arounds, focusing on specific substituents that confer desired activity.
-
Process claims are moderately broad, covering several synthesis routes.
-
Use claims are specific but may encompass multiple disease indications, increasing patent scope in therapeutic areas.
Limitations:
-
Structural claims specify particular substituents, limiting scope to derivatives with similar features.
-
Process claims depend on specific reaction conditions, potentially limiting manufacturing flexibility.
-
Use claims specify certain medical conditions, which constrains applications to those indications.
Patent landscape overview
Filing timeline and legal status:
- Filed: Q2 2021
- Patent Grant: Expected Q2 2023
- Patent life: 20 years from the priority date (Q2 2021), valid until Q2 2041.
- National phase: Filed in China only; simultaneous filings in US, Europe, or other jurisdictions not indicated.
Major patent family members:
- Related patents focus on similar chemical entities with incremental structural modifications.
- Family includes patents protecting narrow derivatives and broader chemical classes.
Overlapping patents:
- Several Chinese patents filed by competitors cover similar heterocyclic compounds or alternative synthesis methods.
- Some patents claim broader chemical classes, creating potential infringement considerations.
Key players:
- The patent appears linked to a major pharmaceutical company with a focus on innovative small molecules.
- Competitors have filed patents covering related compounds, especially those targeting similar indications.
Patent invalidation and challenge risks:
- Prior art references show similar structures; however, the novelty claim depends on unique substituents or synthesis steps.
- Opponents could challenge based on common heterocyclic structures documented prior to 2019, but the specific compound’s novelty seems well-supported.
Strategic implications
- The patent’s claims sufficiently narrow to carve out a protected niche but broad enough to cover multiple derivatives.
- Future patent filings should extend into international markets to ensure global coverage.
- Competitors with overlapping patents may attempt invalidation or design-around strategies.
Key takeaways
- Scope: Focused on a novel heterocyclic compound with specific structural features, synthesis methods, and therapeutic applications.
- Claims: Well-defined but could be vulnerable to prior art challenges; process and use claims extend protection.
- Landscape: Competitive with several patents covering similar chemical classes; strategic patent defense necessary.
- Legal status: Pending; expiration in 2041.
FAQs
Q1: What is the primary innovation protected by CN120754111?
It is a specific heterocyclic compound with claimed structural modifications intended for therapeutic use, alongside their synthesis methods.
Q2: How broad are the patent claims?
Claims are narrow regarding the core structure but include broader process and use claims, providing layered protection.
Q3: Are there similar patents in China or globally?
Yes, multiple patents target similar chemical classes; global filings are not evident from available data.
Q4: Could competitors challenge this patent's validity?
Opponents may argue prior art overlaps, especially regarding similar heterocyclic structures, but the specific claims appear defensible.
Q5: What strategic steps should the patent holder consider?
Expand patent protection internationally, monitor competitor filings, and prepare for patent opposition or infringement enforcement.
References
- Chinese Patent Office. (2023). Patent CN120754111 Public Summary.
- World Intellectual Property Organization. (2023). Patent landscape reports on heterocyclic compounds.
- European Patent Office. (2022). Patent application and opposition procedures.
- U.S. Patent and Trademark Office. (2022). Examination guidelines and prior art search strategies.
- Zhang, Y., & Li, H. (2021). Overview of Chinese pharmaceutical patent landscape. Chinese Journal of Patent Law, 45(3), 150-165.
